PURPOSE: The dopamine D(2) receptor (D2R) is important in the mediation of addiction. [(123)I]iodobenzamide (IBZM), a SPECT ligand for the D2R, has been used for in vivo studies of D2R availability in humans, monkeys, and rats. Although mouse models are important in the study of addiction, [(123)I]IBZM has not been used in mice SPECT studies. This study evaluates the use of [(123)I]IBZM for measuring D2R availability in mice. METHODS: Pharmacokinetics of [(123)I]IBZM in mice were studied with pinhole SPECT imaging after intravenous (i.v.) injection of [(123)I]IBZM (20, 40, and 70 MBq). In addition, the ability to measure the release of endogenous dopamine after amphetamine administration with [(123)I]IBZM SPECT was investigated. Thirdly, i.v. administration, the standard route of administration, and intraperitoneal (i.p.) administration of [(123)I]IBZM were compared. RESULTS: Specific binding of [(123)I]IBZM within the mouse striatum could be clearly visualized with SPECT. Peak specific striatal binding ratios were reached around 90 min post-injection. After amphetamine administration, the specific binding ratios of [(123)I]IBZM decreased significantly (-27.2%; n = 6; p = 0.046). Intravenous administration of [(123)I]IBZM led to significantly higher specific binding than i.p. administration of the same dose. However, we found that i.v. administration of a dose of 70 MBq [(123)I]IBZM might result in acute ethanol intoxication because ethanol is used as a preparative aid for the routine production of [(123)I]IBZM. CONCLUSIONS: Imaging of D2R availability and endogenous dopamine release in mice is feasible using [(123)I]IBZM single pinhole SPECT. Using commercially produced [(123)I]IBZM, a dose of 40 MBq injected i.v. can be recommended.
PURPOSE: The dopamine D(2) receptor (D2R) is important in the mediation of addiction. [(123)I]iodobenzamide (IBZM), a SPECT ligand for the D2R, has been used for in vivo studies of D2R availability in humans, monkeys, and rats. Although mouse models are important in the study of addiction, [(123)I]IBZM has not been used in mice SPECT studies. This study evaluates the use of [(123)I]IBZM for measuring D2R availability in mice. METHODS: Pharmacokinetics of [(123)I]IBZM in mice were studied with pinhole SPECT imaging after intravenous (i.v.) injection of [(123)I]IBZM (20, 40, and 70 MBq). In addition, the ability to measure the release of endogenous dopamine after amphetamine administration with [(123)I]IBZM SPECT was investigated. Thirdly, i.v. administration, the standard route of administration, and intraperitoneal (i.p.) administration of [(123)I]IBZM were compared. RESULTS: Specific binding of [(123)I]IBZM within the mouse striatum could be clearly visualized with SPECT. Peak specific striatal binding ratios were reached around 90 min post-injection. After amphetamine administration, the specific binding ratios of [(123)I]IBZM decreased significantly (-27.2%; n = 6; p = 0.046). Intravenous administration of [(123)I]IBZM led to significantly higher specific binding than i.p. administration of the same dose. However, we found that i.v. administration of a dose of 70 MBq [(123)I]IBZM might result in acute ethanol intoxication because ethanol is used as a preparative aid for the routine production of [(123)I]IBZM. CONCLUSIONS: Imaging of D2R availability and endogenous dopamine release in mice is feasible using [(123)I]IBZM single pinhole SPECT. Using commercially produced [(123)I]IBZM, a dose of 40 MBq injected i.v. can be recommended.
Authors: Drake Morgan; Kathleen A Grant; H Donald Gage; Robert H Mach; Jay R Kaplan; Osric Prioleau; Susan H Nader; Nancy Buchheimer; Richard L Ehrenkaufer; Michael A Nader Journal: Nat Neurosci Date: 2002-02 Impact factor: 24.884
Authors: Dean F Wong; Hiroto Kuwabara; David J Schretlen; Katherine R Bonson; Yun Zhou; Ayon Nandi; James R Brasić; Alane S Kimes; Marika A Maris; Anil Kumar; Carlo Contoreggi; Jonathan Links; Monique Ernst; Olivier Rousset; Stephen Zukin; Anthony A Grace; Jae Sung Lee; Charles Rohde; Donald R Jasinski; Albert Gjedde; Edythe D London Journal: Neuropsychopharmacology Date: 2006-09-13 Impact factor: 7.853
Authors: J B Habraken; K de Bruin; M Shehata; J Booij; R Bennink; B L van Eck Smit; E Busemann Sokole Journal: J Nucl Med Date: 2001-12 Impact factor: 10.057
Authors: Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; Jean Logan; Anna-Rose Childress; Millard Jayne; Yeming Ma; Christopher Wong Journal: J Neurosci Date: 2006-06-14 Impact factor: 6.167
Authors: Michael A Nader; Drake Morgan; H Donald Gage; Susan H Nader; Tonya L Calhoun; Nancy Buchheimer; Richard Ehrenkaufer; Robert H Mach Journal: Nat Neurosci Date: 2006-07-09 Impact factor: 24.884
Authors: N D Volkow; G J Wang; M W Fischman; R W Foltin; J S Fowler; N N Abumrad; S Vitkun; J Logan; S J Gatley; N Pappas; R Hitzemann; C E Shea Journal: Nature Date: 1997-04-24 Impact factor: 49.962
Authors: Jeffrey W Dalley; Tim D Fryer; Laurent Brichard; Emma S J Robinson; David E H Theobald; Kristjan Lääne; Yolanda Peña; Emily R Murphy; Yasmene Shah; Katrin Probst; Irina Abakumova; Franklin I Aigbirhio; Hugh K Richards; Young Hong; Jean-Claude Baron; Barry J Everitt; Trevor W Robbins Journal: Science Date: 2007-03-02 Impact factor: 47.728
Authors: M Pissarek; J Meyer-Kirchrath; T Hohlfeld; S Vollmar; A M Oros-Peusquens; U Flögel; C Jacoby; U Krügel; N Schramm Journal: Eur J Nucl Med Mol Imaging Date: 2009-05-07 Impact factor: 9.236
Authors: Susanne Nikolaus; Christina Antke; Markus Beu; Konstantin Kley; Andreas Wirrwar; Joseph P Huston; Hans-Wilhelm Müller Journal: Eur J Nucl Med Mol Imaging Date: 2010-11-26 Impact factor: 9.236
Authors: Monique R Bernsen; Pieter E B Vaissier; Roel Van Holen; Jan Booij; Freek J Beekman; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2014-05 Impact factor: 9.236